{"altmetric_id":2798792,"counts":{"readers":{"mendeley":23,"citeulike":0,"connotea":0},"facebook":{"unique_users_count":1,"unique_users":["588931371162191"],"posts_count":1},"total":{"posts_count":10},"twitter":{"unique_users_count":8,"unique_users":["IreneMangues","ISPORJournals","Sulais99","ISPOREcuador","RareDxResearch","danblain","mjmorenov","eerr_es"],"posts_count":9}},"selected_quotes":["#ViH Article in Press: Toward a Functional Definition of a #RareDisease for Regulatory Authorities Funding Agencies","#ViH Vol.17 Iss.8 Highlight: Toward a Functional Definition of a #RareDisease","Cndian authors suggest functionl #raredisease def based on feasiblty of measuring new tx efficacy w RCT"],"citation":{"abstract":"The designation of a disease as \"rare\" is associated with some substantial benefits for companies involved in new drug development, including expedited review by regulatory authorities and relaxed criteria for reimbursement. How \"rare disease\" is defined therefore has major financial implications, both for pharmaceutical companies and for insurers or public drug reimbursement programs. All existing definitions are based, somewhat arbitrarily, on disease incidence or prevalence.","abstract_source":"pubmed","altmetric_jid":"4f6fa5153cf058f6100036ec","authors":["Clarke JT","Coyle D","Evans G","Martin J","Winquist E","Joe T.R. Clarke","Doug Coyle","Gerald Evans","Janet Martin","Eric Winquist"],"doi":"10.1016\/j.jval.2014.08.2672","endpage":"761","first_seen_on":"2014-10-21T18:18:10+00:00","issns":["1098-3015","10983015"],"issue":"8","journal":"Value in Health (Elsevier Science)","last_mentioned_on":1429697234,"links":["https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?rc=9&redirect=http%3A%2F%2Fwww.valueinhealthjournal.com%2Farticle%2FS1098-3015%252814%252904622-1%2Fabstract&code=jval-site","http:\/\/www.sciencedirect.com\/science?_ob=GatewayURL&_origin=IRSSSEARCH&_method=citationSearch&_piikey=S1098301514046221&_version=1&md5=755e6d2f19849977011ad37e1c963070","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?rc=9&redirect=http%3A%2F%2Fwww.valueinhealthjournal.com%2Farticle%2FS1098-3015%252814%252904622-1%2Fabstract%3Frss%3Dyes&code=jval-site","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?rc=8&redirect=http%3A%2F%2Fwww.valueinhealthjournal.com%2Farticle%2FS1098-3015%252814%252904622-1%2Fabstract&code=jval-site","https:\/\/secure.jbs.elsevierhealth.com\/action\/getSharedSiteSession?rc=8&redirect=http%3A%2F%2Fwww.valueinhealthjournal.com%2Farticle%2FS1098-3015%252814%252904622-1%2Ffulltext&code=jval-site","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25498770?dopt=Abstract&utm_source=twitterfeed&utm_medium=twitter"],"pdf_url":"http:\/\/www.valueinhealthjournal.com\/article\/S1098301514046221\/pdf","pmid":"25498770","pubdate":"2014-12-15T00:00:00+00:00","publisher":"Elsevier","publisher_subjects":[{"name":"Public Health And Health Services","scheme":"era"},{"name":"Applied Economics","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"757","subjects":["pharmacology"],"title":"Toward a functional definition of a \"rare disease\" for regulatory authorities and funding agencies.","type":"article","uri":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301514046221","volume":"17","mendeley_url":"http:\/\/www.mendeley.com\/research\/toward-functional-definition-rare-disease-regulatory-authorities-funding-agencies"},"altmetric_score":{"score":6.3,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":6.3},"context_for_score":{"all":{"total_number_of_other_articles":7103054,"mean":6.3015791074597,"rank":1061984,"this_scored_higher_than_pct":85,"this_scored_higher_than":6038491,"rank_type":"exact","sample_size":7103054,"percentile":85},"similar_age_3m":{"total_number_of_other_articles":196850,"mean":7.5590489156665,"rank":34802,"this_scored_higher_than_pct":82,"this_scored_higher_than":161926,"rank_type":"exact","sample_size":196850,"percentile":82},"this_journal":{"total_number_of_other_articles":1356,"mean":3.233532103321,"rank":113,"this_scored_higher_than_pct":91,"this_scored_higher_than":1243,"rank_type":"exact","sample_size":1356,"percentile":91},"similar_age_this_journal_3m":{"total_number_of_other_articles":27,"mean":2.5268461538462,"rank":2,"this_scored_higher_than_pct":92,"this_scored_higher_than":25,"rank_type":"exact","sample_size":27,"percentile":92}}},"demographics":{"poster_types":{"member_of_the_public":8},"users":{"twitter":{"cohorts":{"Members of the public":8}},"mendeley":{"by_status":{"Librarian":1,"Student  > Doctoral Student":4,"Researcher":2,"Student  > Ph. D. Student":2,"Student  > Postgraduate":2,"Student  > Master":5,"Other":7},"by_discipline":{"Medicine and Dentistry":12,"Social Sciences":3,"Agricultural and Biological Sciences":3,"Business, Management and Accounting":2,"Biochemistry, Genetics and Molecular Biology":1,"Unspecified":1,"Pharmacology, Toxicology and Pharmaceutical Science":1}}},"geo":{"twitter":{"EC":1,"CA":1,"CO":1,"ES":1},"mendeley":{"AT":1,"US":1,"BR":1,"ES":1}}},"posts":{"facebook":[{"title":"Toward a Functional Definition of a \u201cRare Disease\u201d for Regulatory Authorities and Funding Agencies","url":"https:\/\/www.facebook.com\/588931371162191\/posts\/725512467504080","license":"public","citation_ids":[2798792],"posted_on":"2014-10-23T01:38:19+00:00","summary":"#HealthEconJA Toward a Functional Definition of a \u201cRare Disease\u201d for Regulatory Authorities and Funding Agencies www.sciencedirect.com","author":{"name":"Healtheconbot","url":"https:\/\/www.facebook.com\/588931371162191","facebook_wall_name":"Healtheconbot","image":"https:\/\/graph.facebook.com\/588931371162191\/picture","id_on_source":"588931371162191"}}],"twitter":[{"url":"https:\/\/twitter.com\/IreneMangues\/status\/534480054399414272","license":"datasift","citation_ids":[2798792],"posted_on":"2014-11-17T22:55:49+00:00","author":{"name":"Irene Mangues","image":"https:\/\/pbs.twimg.com\/profile_images\/3760596171\/38b1f492cdcd32c3e74e8881f8fe1ffa_normal.jpeg","description":"Farmac\u00e8utica BCOP. Lleida.","id_on_source":"IreneMangues","tweeter_id":"1483535203","geo":{"lt":null,"ln":null},"followers":545},"tweet_id":"534480054399414272"},{"url":"https:\/\/twitter.com\/ISPORJournals\/status\/537245731653189632","license":"datasift","citation_ids":[2798792],"posted_on":"2014-11-25T14:05:38+00:00","author":{"name":"ISPORJournals","url":"http:\/\/www.ispor.org","image":"https:\/\/pbs.twimg.com\/profile_images\/447002826565107712\/aTN6nOhE_normal.jpeg","description":"ISPORJournals is the official Twitter account for Value in Health, Value in Health Regional Issues, and Value & Outcomes Spotlight (formerly ISPOR CONNECTIONS).","id_on_source":"ISPORJournals","tweeter_id":"614531669","geo":{"lt":null,"ln":null},"followers":1674},"tweet_id":"537245731653189632"},{"url":"https:\/\/twitter.com\/Sulais99\/status\/537254856566657024","license":"datasift","rt":["ISPORJournals"],"citation_ids":[2798792],"posted_on":"2014-11-25T14:41:54+00:00","author":{"name":"AbdulAziz  Alotaibi","image":"https:\/\/pbs.twimg.com\/profile_images\/894078164569387009\/3EUWgMEK_normal.jpg","description":"Pharmacist, Head Assistant of Medicines Division, Interested in Medicines Procurement & Pharmacoeconomics.","id_on_source":"Sulais99","tweeter_id":"542876819","geo":{"lt":null,"ln":null},"followers":409},"tweet_id":"537254856566657024"},{"url":"https:\/\/twitter.com\/ISPOREcuador\/status\/537819393473126400","license":"datasift","rt":["ISPORJournals"],"citation_ids":[2798792],"posted_on":"2014-11-27T04:05:10+00:00","author":{"name":"ISPOR Ecuador","url":"http:\/\/www.isporecuador.org","image":"https:\/\/pbs.twimg.com\/profile_images\/440483738640596992\/VSxYhO-__normal.jpeg","description":"El cap\u00edtulo regional de ISPOR Ecuador se conform\u00f3 en abril del 2010 con el fin de promover la farmacoeconom\u00eda y la investigaci\u00f3n de resultados en Ecuador.","id_on_source":"ISPOREcuador","tweeter_id":"2370424932","geo":{"lt":-2,"ln":-77.5,"country":"EC"},"followers":67},"tweet_id":"537819393473126400"},{"url":"https:\/\/twitter.com\/RareDxResearch\/status\/524625543111512068","license":"datasift","citation_ids":[2798792],"posted_on":"2014-10-21T18:17:31+00:00","author":{"name":"Rare Disease Team","url":"http:\/\/www.rare-diseases.ca","image":"https:\/\/pbs.twimg.com\/profile_images\/2560130961\/tde9u4gi217xx56himf1_normal.jpeg","description":"A Canadian research team focusing on rare disease policy.","id_on_source":"RareDxResearch","tweeter_id":"792235213","geo":{"lt":60.10867,"ln":-113.64258,"country":"CA"},"followers":4049},"tweet_id":"524625543111512068"},{"url":"https:\/\/twitter.com\/danblain\/status\/541975275568136192","license":"datasift","citation_ids":[2798792],"posted_on":"2014-12-08T15:19:09+00:00","author":{"name":"Danielle Blain","url":"https:\/\/www.linkedin.com\/pub\/danielle-blain-msc\/13\/483\/467","image":"https:\/\/pbs.twimg.com\/profile_images\/491568687845892097\/e1jutkam_normal.jpeg","description":"Manager in Canadian patient association. Interests in #orphandiseases, #neurodegenerative & #parkinson . Tweets are my own.","id_on_source":"danblain","tweeter_id":"79597270","geo":{"lt":null,"ln":null},"followers":321},"tweet_id":"541975275568136192"},{"url":"https:\/\/twitter.com\/ISPORJournals\/status\/549954445141082113","license":"datasift","citation_ids":[2798792],"posted_on":"2014-12-30T15:45:32+00:00","author":{"name":"ISPORJournals","url":"http:\/\/www.ispor.org","image":"https:\/\/pbs.twimg.com\/profile_images\/447002826565107712\/aTN6nOhE_normal.jpeg","description":"ISPORJournals is the official Twitter account for Value in Health, Value in Health Regional Issues, and Value & Outcomes Spotlight (formerly ISPOR CONNECTIONS).","id_on_source":"ISPORJournals","tweeter_id":"614531669","geo":{"lt":null,"ln":null},"followers":1674},"tweet_id":"549954445141082113"},{"url":"https:\/\/twitter.com\/mjmorenov\/status\/549955084277518337","license":"datasift","rt":["ISPORJournals"],"citation_ids":[2798792],"posted_on":"2014-12-30T15:48:04+00:00","author":{"name":"Mabel Moreno","url":"https:\/\/www.youtube.com\/watch?v=yuTMWgOduFM","image":"https:\/\/pbs.twimg.com\/profile_images\/785343740516925440\/JdlbdBV8_normal.jpg","description":"\"Estar vivo es sumamente peligroso. Si no quiere peligro, mu\u00e9rase, porque a los muertos no les pasa nada\". Rodolfo Llin\u00e1s.","id_on_source":"mjmorenov","tweeter_id":"377452471","geo":{"lt":4.25,"ln":-74.18333,"country":"CO"},"followers":407},"tweet_id":"549955084277518337"},{"url":"https:\/\/twitter.com\/eerr_es\/status\/590819139532423168","license":"datasift","citation_ids":[2798792],"posted_on":"2015-04-22T10:07:14+00:00","author":{"name":"EnfermedadesRaras.es","url":"http:\/\/www.enfermedadesraras.es","image":"https:\/\/pbs.twimg.com\/profile_images\/2631511713\/0750f88e51f844df2c68f65ace233f92_normal.jpeg","description":"Web dedicada a la informaci\u00f3n sobre enfermedades raras.","id_on_source":"eerr_es","tweeter_id":"512511489","geo":{"lt":40,"ln":-4,"country":"ES"},"followers":6217},"tweet_id":"590819139532423168"}]}}